NEJM study suggests Pfizer, BMS drug superior to Sanofi drug in VTE
This article was originally published in Scrip
Executive Summary
Results reported this week in the New England Journal of Medicine showed that Pfizer's and Bristol-Myers Squibb's apixaban, an oral highly selective Factor Xa inhibitor, was statistically superior to Sanofi Aventis' Lovenox (enoxaparin) in reducing the incidence of venous thromboembolism (VTE) in patients undergoing elective total hip replacement surgery.